Filing Flows › Companies › Janux Therapeutics › Timeline
Janux Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−38.5% to $17.63
Janux Therapeutics (JANX) stock fell 38% over the last 252 sessions, to $17.63. On the way it reported 5 quarters, its insiders filed 8 open-market trades, and the company filed 2 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 30.4% | −12.4% (−7.9% vs SPY) | — | — |
| Aug 6, 2026 | Earnings | Earnings: missed the EPS estimate by -20.9% | +0.6% (+0.8% vs SPY) | +4.1% (+3.8% vs SPY) | +21.3% (+20.9% vs SPY) |
| Jun 2, 2026 | Insider sale | Doyle Janeen Noel sold $57K | −4.5% (−4.6% vs SPY) | −6.5% (−3.9% vs SPY) | +1.7% (+3.2% vs SPY) |
| May 11, 2026 | Insider sale | Dobek Maria sold $29K | +0.4% (+0.2% vs SPY) | −2.0% (−2.2% vs SPY) | −4.0% (−3.9% vs SPY) |
| May 7, 2026 | Earnings | Earnings: beat the EPS estimate by 25.0% | −0.5% (−0.2% vs SPY) | −0.1% (−1.2% vs SPY) | −9.0% (−9.5% vs SPY) |
| Apr 28, 2026 | 8-K | Directors and officers: departures, appointments, pay | −2.7% (−2.7% vs SPY) | −1.2% (−2.9% vs SPY) | +1.6% (−4.2% vs SPY) |
| Feb 26, 2026 | Earnings | Earnings: beat the EPS estimate by 20.5% | +0.7% (+1.3% vs SPY) | +4.6% (+5.8% vs SPY) | −0.5% (+6.4% vs SPY) |
| Jan 22, 2026 | 8-K | Material definitive agreement | −2.2% (−2.2% vs SPY) | −9.0% (−9.8% vs SPY) | −12.4% (−11.5% vs SPY) |
| Jan 2, 2026 | Insider sale | Winter Charles M. sold $33K | −1.1% (−1.3% vs SPY) | +0.8% (−0.3% vs SPY) | +1.4% (−0.6% vs SPY) |
| Jan 2, 2026 | Insider sale | Meyer Andrew Hollman sold $26K | −1.1% (−1.3% vs SPY) | +0.8% (−0.3% vs SPY) | +1.4% (−0.6% vs SPY) |
| Jan 2, 2026 | Insider sale | McIver Zachariah sold $37K | −1.1% (−1.3% vs SPY) | +0.8% (−0.3% vs SPY) | +1.4% (−0.6% vs SPY) |
| Jan 2, 2026 | Insider sale | Dobek Maria sold $20K | −1.1% (−1.3% vs SPY) | +0.8% (−0.3% vs SPY) | +1.4% (−0.6% vs SPY) |
| Jan 2, 2026 | Insider sale | DiRaimondo Thomas sold $34K | −1.1% (−1.3% vs SPY) | +0.8% (−0.3% vs SPY) | +1.4% (−0.6% vs SPY) |
| Jan 2, 2026 | Insider sale | Campbell David Alan sold $111K | −1.1% (−1.3% vs SPY) | +0.8% (−0.3% vs SPY) | +1.4% (−0.6% vs SPY) |
| Nov 6, 2025 | Earnings | Earnings: beat the EPS estimate by 36.3% | +4.0% (+5.1% vs SPY) | +3.5% (+2.6% vs SPY) | −51.2% (−52.3% vs SPY) |
Insiders’ record here
In the year on the chart, Janux Therapeutics' insiders reported 0 open-market buys ($0) and 8 sales ($347K). Of the 8 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale +13.0%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Janux Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.